Therapy for Patients with Chronic Phase-chronic Myeloid Leukemia Previously Treated with ⩾2 Tyrosine Kinase Inhibitors: a Systematic Literature Review

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2023 Dec 18

PMID 38105770

Authors

Ehab Atallah

Lovneet Saini

Rodrigo Maegawa

Tanvi Rajput

Regina Corbin

Ricardo Viana

Affiliations

Soon will be listed here.

Abstract

Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and second-line (2 L) setting. Treatment after 2 L is not clearly established.

Objective: The objective of this study was to summarize the available evidence to compare the efficacy and safety of interventions in the treatment of CP-CML patients who had received ⩾2 prior TKIs.

Design: A systematic literature review was performed.

Data Source And Methods: A systematic literature review (SLR) of studies published until May 2021, reporting clinical outcomes in adult patients with CP-CML who had received ⩾ 2 prior TKIs was performed. Studies were identified through the database searches via Ovid platform (Embase, MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations, and Cochrane Central Register of Controlled Trials), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), bibliographic search of relevant reviews, and proceedings from the previous 3 years of the key conferences in the field of oncology.

Results: Our search identified 38 relevant studies. Among the identified studies of the current third-line treatments, the major molecular response (MMR) rate for ponatinib was 19.0-66.7%, 23.3-25.5% for asciminib, 19.2% for omacetaxine, and 13.2% for bosutinib at 6 months. The complete cytogenetic response (CCyR) rate was 21.4-64.8% for ponatinib, 38.7-40.8% for asciminib, 18-24.2% for bosutinib, and 16.1% for omacetaxine at 6 months.

Conclusion: The findings from current SLR demonstrated the lack of data for patients with CML treated with ⩾2 TKIs. TKIs such as asciminib, ponatinib, and bosutinib are valid options for those patients. Further research is needed to identify the best treatment option for patients with CML receiving later lines of therapy.

Citing Articles

CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML.

Absar M, Alanazi N, Siyal A, Shammas M, Mahmood A, Basit S J Popul Ther Clin Pharmacol. 2024; 29(2):311-320.

PMID: 38465242 PMC: 10923263. DOI: 10.53555/jptcp.v29i02.4161.

References

Rea D, Mauro M, Boquimpani C, Minami Y, Lomaia E, Voloshin S . A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021; 138(21):2031-2041. PMC: 9728405. DOI: 10.1182/blood.2020009984. View

Khoury H, Cortes J, Kantarjian H, Gambacorti-Passerini C, Baccarani M, Kim D . Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012; 119(15):3403-12. PMC: 4916559. DOI: 10.1182/blood-2011-11-390120. View

Oriana C, Martin H, Toby P, Chris C, Ruth G, Claudius R . Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value Health. 2013; 16(6):1081-90. DOI: 10.1016/j.jval.2013.07.004. View

Garcia-Gutierrez V, Milojkovic D, Hernandez-Boluda J, Claudiani S, Martin Mateos M, Casado-Montero L . Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol. 2018; 98(2):321-330. DOI: 10.1007/s00277-018-3507-2. View

Eskazan A, Keskin D . Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol. 2017; 8(9):237-243. PMC: 5639974. DOI: 10.1177/2040620717719851. View

Cortes J, Khoury H, Kantarjian H, Lipton J, Kim D, Schafhausen P . Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016; 91(12):1206-1214. PMC: 5303616. DOI: 10.1002/ajh.24536. View

Latagliata R, Attolico I, Trawinska M, Capodanno I, Annunziata M, Elena C . Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. Hematol Oncol. 2021; 39(3):401-408. DOI: 10.1002/hon.2851. View

Hoglund M, Sandin F, Simonsson B . Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015; 94 Suppl 2:S241-7. DOI: 10.1007/s00277-015-2314-2. View

Cortes J, Lang F . Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021; 14(1):44. PMC: 7976694. DOI: 10.1186/s13045-021-01055-9. View

10.

Cortes J, Digumarti R, Parikh P, Wetzler M, Lipton J, Hochhaus A . Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013; 88(5):350-4. PMC: 5558840. DOI: 10.1002/ajh.23408. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

12.

Ongoren S, Eskazan A, Suzan V, Savci S, Erdogan Ozunal I, Berk S . Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology. 2017; 23(4):212-220. DOI: 10.1080/10245332.2017.1385193. View

13.

Cortes J, Lipton J, Rea D, Digumarti R, Chuah C, Nanda N . Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012; 120(13):2573-80. PMC: 4916583. DOI: 10.1182/blood-2012-03-415307. View

14.

Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F . European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984. PMC: 7214240. DOI: 10.1038/s41375-020-0776-2. View

15.

Devos T, Havelange V, Theunissen K, Meers S, Benghiat F, Gadisseur A . Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry. Ann Hematol. 2021; 100(7):1723-1732. PMC: 8195783. DOI: 10.1007/s00277-021-04507-x. View

16.

Hochhaus A, Saussele S, Rosti G, Mahon F, Janssen J, Hjorth-Hansen H . Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv41-iv51. DOI: 10.1093/annonc/mdx219. View

17.

Hochhaus A, Breccia M, Saglio G, Garcia-Gutierrez V, Rea D, Janssen J . Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020; 34(6):1495-1502. PMC: 7266739. DOI: 10.1038/s41375-020-0842-9. View

18.

Ribeiro B, Miranda E, de Albuquerque D, Delamain M, Oliveira-Duarte G, Almeida M . Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Clinics (Sao Paulo). 2015; 70(8):550-5. PMC: 4518767. DOI: 10.6061/clinics/2015(08)04. View

19.

Cortes J, Kantarjian H, Shah N, Bixby D, Mauro M, Flinn I . Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367(22):2075-88. PMC: 3777383. DOI: 10.1056/NEJMoa1205127. View

20.

Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet. 2007; 370(9584):342-50. DOI: 10.1016/S0140-6736(07)61165-9. View